#United States #New York #oncology #Convertible Notes #Nuvation Bio

Nuvation Bio Launches Upsized Offering of Convertible Senior Notes

On June 25, 2026, Nuvation Bio Inc. (NYSE: NUVB), a leading global oncology firm dedicated to addressing significant challenges in cancer treatment, made a pivotal announcement regarding its underwritten offering of convertible senior notes. This offering has reached an impressive total of $250 million, which has been increased from an earlier projection of $200 million. The company expects to finalize the sale of these notes on June 30, 2026, contingent upon standard closing procedures.

Investment Highlights

The convertible senior notes, bearing an interest rate of 0.75%, are scheduled for maturity on July 1, 2032. Nuvation Bio has also provided underwriters with the option to purchase an additional $37.5 million worth of notes, allowing them flexibility to meet any over-allotments.

The notes will not be secured, making them general obligations of Nuvation Bio, with interest payments occurring on January 1 and July 1 each year, commencing from January 2027. With this offering, Nuvation Bio anticipates net proceeds of roughly $241.2 million, which could increase to $277.6 million if the over-allotment option is fully utilized.

Purpose of the Proceeds

Nuvation Bio plans to allocate the proceeds from this offering for various strategic purposes:
1. Covering Costs of Capped Call Transactions: These transactions are designed to offset potential dilution stemming from the conversion of notes.
2. Repayment of Senior Secured Loan Obligations: The company intends to fully clear its existing obligations under its senior secured loan agreement.
3. General Corporate Purposes: The funds will help in financing working capital, operating expenses, capital expenditures, and additional administrative costs. Should the over-allotment option be executed, further portions of the proceeds will be used for additional capped call transactions.

Mechanics of Conversion

Holders of the notes can convert their holdings under specific conditions until the business day before April 1, 2032. Post that date, they can convert their notes without restriction until the second trading day before maturity. Upon conversion, Nuvation Bio has the discretion to deliver cash, shares of its Class A common stock, or a fusion of both.

The initial conversion rate is set at 127.4941 shares of Class A common stock per $1,000 of notes, equating to a conversion price of about $7.84 per share. This suggests a 35% premium based on the last closing price of the stock at the time of the announcement.

Redemption and Repurchase Options

The company will not redeem notes before July 6, 2029 but holds the right to redeem notes at cash value if its Class A common stock price meets specific thresholds, signaling favorable market conditions. In scenarios of a 'fundamental change,' noteholders may also require repurchase of their notes at the principal amount plus accrued interest.

Strategic Partnerships

In conjunction with the note offering, Nuvation Bio has coordinated capped call transactions with select financial institutions, aiming to shield against dilution for existing shareholders. The cap price for these transactions is set at $10.4580, a premium over the current market price of Class A common stock.

The initiation of these financial moves signifies Nuvation Bio's proactive strategy to facilitate its growth in the competitive oncology landscape while ensuring financial stability during its operational pursuits.

As an organization, Nuvation Bio is committed to delivering transformative therapies aimed at enhancing patient outcomes in oncology, with a diverse pipeline including innovative compounds such as the next-generation ROS1 inhibitor, taletrectinib (IBTROZI®).

For further details on the offering, interested parties can access the relevant documents and disclosures on the Securities and Exchange Commission's website. This offering signifies not only a notable capital raise for the company but also a strategic repositioning as it aims to solidify its market presence in oncology therapeutics.